AbbVie to Buy Apogee Therapeutics for $10.9 Billion

AbbVie has agreed to acquire Apogee Therapeutics in a transaction valued at $10.9 billion. This strategic acquisition is designed to enhance AbbVie's presence within the dermatology sector by integrating treatments for atopic dermatitis, also known as eczema, into its existing product portfolio. The deal was discussed by Sam Fazeli on Bloomberg Open Interest, highlighting the company's expansion into specialized skin care therapies to drive growth and broaden its therapeutic reach in the global market.